Table 1.

Baseline characteristics of the low and high calprotectin groups

	Low Calprotectin	High Calprotectin	p value
Number	11	11
Age Mean ± SD (years)	13.4 ± 3.30	14.4 ± 2.20	0.414
Disease Duration Mean ± SD (months)	30.7 ± 13.5	29.8 ±13.8	0.878
Time on biologics Mean ± SD (months)	18.6 ± 11.4	19.1 ± 13.8	0.921
Height (z score)	0.534 ± 1.35	-0.689 ± 0.689	0.025
BMI (z score)	0.174 ± 1.17	0.0648 ± 1.24	0.846
Biological therapy	Infliximab 91% Vedolizumab 9%	Infliximab 91% Vedolizumab 9%	0.99
Immunomodulator	Azathioprine 18% Methotrexate 18% Mercaptopurine 9%	Azathioprine 45% Methotrexate 0% Mercaptopurine 0%	-
Disease location	L1 0% L2 45% L3 45% L4a/b 54% Perianal 9%	L1 9% L2 36% L3 45% L4a/b 63% Perianal 27%	-

P values calculated using unpaired unequal variance t test (Welch’s test) for continuous variables, and Chi squared test for categorical variables where validity requirements met